Cynthia E. Schairer, PhD, Caryn Kseniya Rubanovich, MS, and Cinnamon S. Bloss, PhD
Questions about data privacy need to be addressed when research institutions negotiate with companies developing mobile health applications. Commercial terms of use and data sharing notifications should be reviewed before use in human subject research settings.
AMA J Ethics. 2018;20(9):E864-872. doi:
10.1001/amajethics.2018.864.
Judgmentalism applied to patients from poor and marginalized communities exacerbates health inequity and illuminates the importance of contextualizing a patient’s care.
AMA J Ethics. 2021;23(2):E91-96. doi:
10.1001/amajethics.2021.91.
Some refugees’ illness experiences preclude them from testifying and accurately representing their own interests during asylum adjudication proceedings.
AMA J Ethics. 2021;23(2):E132-139. doi:
10.1001/amajethics.2021.132.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"